Author:
Mai Julia,Reiter Gregor S.,Riedl Sophie,Vogl Wolf-Dieter,Sadeghipour Amir,Foos Emma,McKeown Alex,Bogunovic Hrvoje,Schmidt-Erfurth Ursula
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Apellis. FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness. https://investors.apellis.com/news-releases/news-release-details/fda-approves-syfovretm-pegcetacoplan-injection-first-and-only (2023).
2. Liao, D. S. et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: A randomized phase 2 trial. Ophthalmology 127, 186–195. https://doi.org/10.1016/j.ophtha.2019.07.011 (2020).
3. Heier, J. S. et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): Two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet 402, 1434–1448. https://doi.org/10.1016/s0140-6736(23)01520-9 (2023).
4. Astellas. Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy (2023).
5. Khanani, A. M. et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet https://doi.org/10.1016/s0140-6736(23)01583-0 (2023).